NUVB vs AUPH vs PRAX vs KRYS vs FOLD

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 3x trailing P/E (18. 7x forward), making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Aurinia Pharmaceuticals Inc.

(AUPH) is the cheapest at 7. 3x versus Krystal Biotech, Inc. at 43. 4x. On forward P/E, Aurinia Pharmaceuticals Inc. is actually cheaper at 18. 7x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +319. 2%, compared to -58. 3% for Nuvation Bio Inc. (NUVB). Over 10 years, the gap is even starker: KRYS returned +27. 7% versus NUVB's -52. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 61β versus Nuvation Bio Inc. 's 1. 97β — meaning NUVB is approximately 221% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Aurinia Pharmaceuticals Inc.

(AUPH) trades at 18. 7x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 21. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89), +511. 6% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUPH: +511. 6%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NUVB is a small-cap high-growth stock; AUPH is a small-cap high-growth stock; PRAX is a small-cap quality compounder stock; KRYS is a small-cap high-growth stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.